Yes, this is true. IDIX has been known to be on the block. And Merck did make the disclosure you noted.
There has been no news reported that ACHN is on the block (that I know of). They have always contended that that they have all three parts of a HCV cure -- a PI (2684, 1625), a NS5A-I (3102), and a NS5B-I (3422) and planned to develop an in-house combo.
Of course, they will consider a buy-out deal at the right price. But its too early for that.
So I'm not sure if 3422 has been evaluated in-house by any outside parties.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.